As our population continues to grow and age, finding proper healthcare solutions will remain a top concern. Overall, Americans during the second half of this decade have spent nearly trillions on healthcare and that number continues to rise. A similar story is occurring in the developing world. As rising incomes and the new middle class crave many of the same "luxuries" as the west, healthcare spending by these nations will also rise. However, while much of investor attention in the sector has gone towards the major pharmaceutical companies or funds like iShares Dow Jones US Pharmaceuticals (NYSE:IHE), that may not be the best choice. With the "Age of the Blockbuster" coming to an end, big pharma must reposition itself. For investors, that could lead to gains.

TUTORIAL: Retirement Planning

Higher R&D Spending
The major pharmaceutical companies are staring down the barrel of gun. Billions of dollars worth of patented, protected drugs are expected to go generic over the next few years. In 2012 alone, more than billions worth of drugs will lose their patents including Singulair, Viagra and the Sanofi-Aventis (NYSE:SNY) and Bristol-Myers Squibb (NYSE:BMY) gigantic success Plavix. However, in the face of this problem, the majors continue to cut costs, specifically in research and development. For example, GlaxoSmithKline (NYSE:GSK) has extensively cut its R&D costs by closing research facilities and doing less discovery work in-house.

The task of drug innovation has fallen to the biotech sector. Overall R&D expenditures for smaller biotech firms as a percentage of revenue are roughly 108%, versus the 54% for larger firms. Some analysts also estimate that by 2014, biotech drugs will account for almost 50% of the top 100 drugs. This compares to just 28% in 2008 and only 11% in 2000. With some biotech treatments for rare diseases costing thousands, big pharma has been taking notice of biotech's potential. Partnerships between the sectors are on the rise, and more recently acquisition activity has picked. Sanofi's purchase of Genzyme was just the tip of the iceberg. More recently, Israel's Teva Pharmaceuticals (Nasdaq:TEVA) agreed to purchase Cephalon (Nasdaq:CEPH) for $6.2 billion. There is a general need for drugs that treat diseases such as diabetes, hepatitis C, and cancer that have high current demand and favorable demographic trends. With the biotech industry focusing on rare diseases and antibodies, will suit it well going forward.

Healthcare Lotto Tickets
Historically, biotech investing has been described like playing the lottery. Generally, companies within the sector are small labs with just one drug under their belts and the vast numbers of them fail. These companies rise and fall with each round of FDA testing. For investors, Betting on a basket of these companies may be best. Both the SPDR S&P Biotech (NYSE:XBI) and iShares Nasdaq Biotechnology (NYSE:IBB) allow investors to add a wide swath of the industry to a portfolio.

For those investors looking to play the lotto aspect of biotech, Aeterna Zentaris (Nasdaq:AEZS) could be a good bet. The company has a rich pipeline of biotech drugs and its colorectal cancer treatment has entered late stage phase 3 trials. Similarly, small biotech Zalicus (Nasdaq:ZLCS) quality drug pipeline has analysts at Oppenheimer upping the company's share price target to $4.

Finally, for those who wish to play the take-over angle, analysts at Morningstar see Biogen (Nasdaq:BIIB), Seattle Genetics (Nasdaq:SGEN) and BioMarin (Nasdaq:BMRN) as possible acquisition targets from big pharma. These firms have strong pipelines as well as variety of rare disease drugs that could supplement the major pharmaceuticals offerings.

The Bottom Line
In the wake of the big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors. As both the primary driver of new drug innovation as well as being a source of growth for the majors, biotech's dominance in healthcare is assured. For investors, adding a fund like the First Trust NYSE Arca Biotech Index (NYSE:FBT) could do portfolio wonders. (One program is for the poor; the other is for the elderly. Learn which is which. See What's The Difference Between Medicare And Medicaid?)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Mutual Funds & ETFs

    ETF Analysis: SPDR S&P Emerging Markets Dividend

    Learn more about the SDPR S&P Emerging Markets Dividend Fund, a yield-focused exchange-traded fund tracking global emerging economies.
  2. Mutual Funds & ETFs

    ETF Analysis: First Trust Dow Jones Global Sel Div

    Find out about the First Trust Dow Jones Global Select Dividend Index Fund, and learn detailed information about characteristics and suitability of the fund.
  3. Mutual Funds & ETFs

    ETF Analysis: U.S 12 Month Natural Gas

    Learn about the United States 12 Month Natural Gas Fund, an exchange-traded fund that invests in 12-month futures contracts for natural gas.
  4. Mutual Funds & ETFs

    ETF Analysis: iShares Floating Rate Bond

    Explore detailed analysis and information of the iShares Floating Rate Bond ETF, and learn how to use this ETF as a defense against rising interest rates.
  5. Mutual Funds & ETFs

    ETF Analysis: ProShares UltraPro Short S&P500

    Find out information about the ProShares UltraPro Short S&P 500 exchange-traded fund, and learn detailed analysis of its characteristics and suitability.
  6. Mutual Funds & ETFs

    ETF Analysis: SPDR Barclays Investment Grd Fl Rt

    Learn more about the SPDR Barclays Investment Grade Floating Rate Fund, which tracks an index of highly rated floating debt securities.
  7. Mutual Funds & ETFs

    ETF Analysis: ALPS Medical Breakthroughs

    Learn more about a unique and innovative exchange-traded fund (ETF) in the biotechnology industry: the ALPS Medical Breakthroughs Fund.
  8. Mutual Funds & ETFs

    ETF Analysis: iShares US Healthcare

    Learn about the iShares U.S. Healthcare exchange-traded fund, which invests in a wide range of health care providers, hospitals and home care facilities.
  9. Mutual Funds & ETFs

    Top 5 Japan Mutual Funds

    Discover five of the most popular and best-performing mutual funds offering investors direct exposure to equities of Japanese companies.
  10. Mutual Funds & ETFs

    ETF Analysis: BioShares Biotechnology Clinical Trials

    Learn more about the BioShares Biotechnology Clinical Trials Fund, a new and innovative fund focusing on breakthroughs in the health industry.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Exchange-Traded Fund (ETF)

    A security that tracks an index, a commodity or a basket of assets ...
  3. Exchange-Traded Mutual Funds (ETMF)

    Investopedia explains the definition of exchange-traded mutual ...
  4. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  5. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  6. Lion economies

    A nickname given to Africa's growing economies.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. What does a high turnover ratio signify for an investment fund?

    If an investment fund has a high turnover ratio, it indicates it replaces most or all of its holdings over a one-year period. ... Read Full Answer >>
  5. Does index trading increase market vulnerability?

    The rise of index trading may increase the overall vulnerability of the stock market due to increased correlations between ... Read Full Answer >>
  6. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!